Overview
A recent Form 4 filing shows Aaron Freidin, Chief Financial Officer of GRAIL, Inc. (NASDAQ: GRAL), disposed of 3,147 shares of the company’s common stock in a series of transactions completed on March 5 and March 9, 2026. The total proceeds from those sales amounted to $154,061.
Transaction specifics
- On March 5, Freidin sold 655 shares at $53.01 per share.
- On March 9, he sold 2,407 shares at $47.93 per share.
- Also on March 9, 85 shares were sold at $46.74 per share.
The sales were executed at price points ranging from $46.74 to $53.01. As of this report, GRAIL’s stock is trading at $49.82, reflecting a volatile period in which the shares have declined 42% year-to-date while showing a 55% gain over the trailing twelve months.
Post-transaction holdings and filing notes
After the transactions disclosed in the Form 4, Freidin is recorded as directly owning 306,475 shares of GRAIL. The filing’s footnotes specify that the sell orders were automatic sell-to-cover transactions executed by a broker to satisfy withholding tax obligations arising when awards vested and shares were delivered.
Company financials and clinical update
GRAIL released fourth-quarter and full-year 2025 results that were consistent with its preannouncement and, in aggregate, came in ahead of Canaccord Genuity’s projections and the FactSet consensus. The company cited a 35% year-over-year increase in Galleri testing volume as a driver of the better-than-expected results.
At the same time, GRAIL disclosed that its NHS-Galleri clinical study did not meet its primary endpoint of reducing Stage III-IV cancer diagnoses. That outcome has influenced analyst positioning and price targets.
Analyst reactions
- Canaccord Genuity reduced its price target on GRAIL to $80 while retaining a Buy rating.
- TD Cowen reiterated a Hold rating with a $114 price target, noting GRAIL’s early-positioning in multi-cancer early detection.
- Baird initiated coverage with an Outperform rating and set a $113 price target, acknowledging both speculative risk and potential for the Galleri test.
Summary
GRAIL’s CFO executed sell-to-cover trades in March 2026 totaling $154,061. The company reported solid volume-driven revenue performance for 2025 but recorded a key clinical trial that did not achieve its primary endpoint, producing a range of analyst responses and revised price targets.
Key points
- Corporate insider activity: CFO Aaron Freidin sold 3,147 shares in broker-executed sell-to-cover transactions to cover tax withholding.
- Financial performance: GRAIL’s Q4 and full-year 2025 results beat certain analyst estimates, led by a 35% increase in Galleri testing volume.
- Analyst divergence: Following a trial miss on the NHS-Galleri primary endpoint, analysts adjusted price targets and ratings, reflecting differing views on the company’s prospects.
Risks and uncertainties
- Clinical risk: The NHS-Galleri study did not meet its primary endpoint of reducing Stage III-IV cancer diagnoses, introducing uncertainty about clinical efficacy outcomes.
- Market volatility: The stock has experienced notable price swings - down 42% year-to-date despite a 55% gain over the past 12 months - which could affect investor sentiment and trading liquidity.
- Analyst outlook divergence: Mixed ratings and differing price targets from major firms indicate uncertainty in consensus views on valuation and the commercial outlook.
This article presents transaction and company information based on public filings and the company’s reported results. No new financial metrics, dates, or outcomes beyond those disclosed have been introduced.